Hello, everyone, and how are you today? A warm and shiny sun is enveloping the Pharmalot campus this morning, which is a welcome relief given the recent temperatures. We were already warming up, however, with a few cups of delicious stimulation. Our choice today is blueberry, for those interested in such things. Please do join us. After all, firing up the neurons can be a worthwhile exercise. Meanwhile, here is the latest menu of tidbits. We hope you have a grand day or, at least, survive. And if you do, by all means, keep in touch …

Shire (SHPG) has rejected a third offer from Takeda Pharmaceutical (TKPYY), arguing the latest bid from the Japanese drug maker, which was $60 billion, continues to significantly undervalue the company and its growth prospects and pipeline. Takeda has an April 25 deadline to strike a deal. Takeda has been ramping up its takeover ambitions as the company seeks growth overseas amid patent expirations and a shrinking domestic population. Takeda would gain new assets in gastrointestinal diseases and nervous-system ailments, and key treatments that are in the late stages of testing, Bloomberg News points out.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • One must observe that the Pharmalot campus must be a magic place indeed! While our scribe is blessed with warmth and sun, the rest of the area (based on personal observations and the NOAA website) has had clouds, rain and fog pre-sunrise until now.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy